Recent advances on blinatumomab for acute lymphoblastic leukemia

Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Juanjuan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833142/
https://www.ncbi.nlm.nih.gov/pubmed/31709129
http://dx.doi.org/10.1186/s40164-019-0152-y
_version_ 1783466312045953024
author Zhao, Juanjuan
Song, Yongping
Liu, Delong
author_facet Zhao, Juanjuan
Song, Yongping
Liu, Delong
author_sort Zhao, Juanjuan
collection PubMed
description Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B-ALL. This review summarized data from recent clinical trials of blinatumomab for B-ALL treatment.
format Online
Article
Text
id pubmed-6833142
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68331422019-11-08 Recent advances on blinatumomab for acute lymphoblastic leukemia Zhao, Juanjuan Song, Yongping Liu, Delong Exp Hematol Oncol Review Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B-ALL. This review summarized data from recent clinical trials of blinatumomab for B-ALL treatment. BioMed Central 2019-11-06 /pmc/articles/PMC6833142/ /pubmed/31709129 http://dx.doi.org/10.1186/s40164-019-0152-y Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhao, Juanjuan
Song, Yongping
Liu, Delong
Recent advances on blinatumomab for acute lymphoblastic leukemia
title Recent advances on blinatumomab for acute lymphoblastic leukemia
title_full Recent advances on blinatumomab for acute lymphoblastic leukemia
title_fullStr Recent advances on blinatumomab for acute lymphoblastic leukemia
title_full_unstemmed Recent advances on blinatumomab for acute lymphoblastic leukemia
title_short Recent advances on blinatumomab for acute lymphoblastic leukemia
title_sort recent advances on blinatumomab for acute lymphoblastic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833142/
https://www.ncbi.nlm.nih.gov/pubmed/31709129
http://dx.doi.org/10.1186/s40164-019-0152-y
work_keys_str_mv AT zhaojuanjuan recentadvancesonblinatumomabforacutelymphoblasticleukemia
AT songyongping recentadvancesonblinatumomabforacutelymphoblasticleukemia
AT liudelong recentadvancesonblinatumomabforacutelymphoblasticleukemia

Ejemplares similares